<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421887</url>
  </required_header>
  <id_info>
    <org_study_id>MOXI</org_study_id>
    <nct_id>NCT02421887</nct_id>
  </id_info>
  <brief_title>Males, Antioxidants, and Infertility Trial</brief_title>
  <acronym>MOXI</acronym>
  <official_title>Males, Antioxidants, and Infertility (MOXI) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the Males, Antioxidants, and Infertility (MOXI) Trial is to examine whether
      treatment of infertile males with an antioxidant formulation improves male fertility. The
      central hypothesis is that treatment of infertile males with antioxidants will improve sperm
      structure and function, resulting in higher fertilization rates and improved embryo
      development, leading to higher pregnancy and live birth rates. Findings from this research
      will be significant in that they will likely lead to an effective, non-hormonal treatment
      modality for male infertility. An effective treatment for men would also reduce the treatment
      burden on the female partner, lower costs, and provide effective alternatives to couples with
      religious or ethical contraindications to ART (Assisted Reproductive Technology). If
      antioxidants do not improve pregnancy rates, but do improve sperm motility and DNA integrity,
      they could allow for couples with male factor infertility to use less intensive therapies
      such as intrauterine insemination. Male fertility specialists currently prescribe
      antioxidants based on the limited data supporting their use. A negative finding, lack of any
      benefit, would also alter current treatment of infertile males.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>up to 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>up to 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage Rate</measure>
    <time_frame>up to 9 months</time_frame>
    <description>miscarriages per total number of pregnancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Pregnancy</measure>
    <time_frame>up to 7 months</time_frame>
    <description>Time to pregnancy will be the chronologic time from randomization to pregnancy detection in days, in which the pregnancy is defined as an HCG value over 5 on 2 separate occasions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in semen parameters, using WHO 5 criteria</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Samples will be assessed using a standard semen analysis, including assessment of morphology using WHO 5 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of sperm with fragmented DNA</measure>
    <time_frame>3 months</time_frame>
    <description>DNA fragmentation will be measured by TUNEL , SCSA, and Comet assays to determine the percentage of sperm with fragmented DNA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>Antioxidant Supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antioxidant Supplement</intervention_name>
    <description>An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine</description>
    <arm_group_label>Antioxidant Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Couple

          -  12 or more months of infertility (primary or secondary)

          -  Heterosexual

          -  Cohabitating and able to have regular intercourse

        Male:

          -  ≥ 18 years of age

          -  At least one abnormal semen parameter on a semen analysis within the past 6 months:

               -  Sperm concentration ≤15 Million/ml

               -  Total motility ≤40%

               -  Normal morphology (Kruger) ≤4%

               -  DNA fragmentation (SCSA, DNA fragmentation index) &gt;25%

        Female:

          -  ≥18 years of age and ≤40 years of age

          -  For women ≥ 35 years of age, evidence of normal ovarian reserve as assessed by
             menstrual cycle day 3 (+/-2 days) FSH ≤10 IU/L with estradiol ≤ 70 pg/mL, AMH ≥ 1.0
             ng/mL, OR antral follicle count &gt;10 within one year prior to study initiation.

          -  Evidence of at least one patent fallopian tube as determined by an hysterosalpingogram
             or laparoscopy showing at least one patent fallopian tube or a saline infusion
             sonogram showing spillage of contrast material

          -  Regular cycles defined as ≥25 days and ≤35 days in duration

          -  Evidence of ovulation including biphasic basal body temperatures, positive ovulation
             predictor kits, or progesterone level ≥3 ng/ml.

        Exclusion Criteria:

          -  Couple:

               -  Previous sterilization procedures (vasectomy, tubal ligation). The prior
                  procedure may affect study outcomes.

               -  Planning in vitro fertilization in the next 6 months

        Male:

          -  Sperm concentration &lt; 5 million/mL on screening semen analysis

          -  Current use of a medication or drug that would affect reproductive function or
             metabolism (see Appendix C for list)

          -  Current multivitamin or herb use (requires 1 month wash-out)

          -  Current serious medical illnesses, such as cancer, heart disease, or cirrhosis

          -  Current use of anticoagulants

          -  Untreated hypothyroidism

          -  Uncontrolled diabetes mellitus

        Female:

          -  History of surgically or medically confirmed moderate or severe endometriosis

          -  Body mass index &gt;35 kg/m2

          -  Currently pregnant

          -  History of polycystic ovarian syndrome

          -  Current serious medical illnesses, such as cancer, heart disease, or cirrhosis

          -  History of systemic chemotherapy or pelvic radiation

          -  Current use of a medication or drug that would affect reproductive function or
             metabolism
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Eisenberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institue of Child Health and Human Development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nanette Santoro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Z Steiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael P Diamond, MD</last_name>
    <role>Study Director</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard S Legro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelle Cedars, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl R Hansen, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Coutifaris, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heping Zhang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keck School of Medicine of University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center - Women's Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://c2s2.yale.edu/rmn/</url>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Heping Zhang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared with other researchers through the NICHD DASH system. It will be available 6 months after publication of the primary results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

